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I n this issue, we are privileged to have 2 state-of-the-art reviews on the topic of posttraumatic stress disorder (PTSD), written by preeminent authorities in the field. Dr Naomi Breslau provides a critical overview of the epidemiology of PTSD, highlighting sex differences and comorbidity. Dr Gordon Asmundson and colleagues' insightful synthesis of the literature linking PTSD to chronic pain emphasizes clinical and research implications. Both papers contain succinct summaries that will inform readers of cutting-edge thinking in these areas.
Growing up and doing much of my residency training in Canada, I had little exposure to or teaching about PTSD. Many American physicians, on the other hand, have done at least some of their training in Veterans Affairs hospitals and have tended to become more familiar with PTSD through their encounters with the Vietnam Veterans who carry this label. This is a mixed blessing: chronic PTSD in Vietnam Veterans who are still symptomatic decades later tends to be a very difficult-to-treat entity. This may have made some psychiatry trainees in the US skeptical about the nature of PTSD and its treatment. Conversely, Canadian physicians' initial experiences with PTSD patients tend to come from outside the military setting, although it is now becoming clear that Canadian soldiers are by no means immune to PTSD (1) . I recall the first individual with a diagnosis of PTSD I ever treated-although I almost certainly missed prior cases that were misdiagnosed (as panic disorder or major depression, for example). The patient was a young woman who had been the driver in a motor vehicle collision in which her passenger was killed. As Dr Breslau points out in her article, nonmilitary trauma is by far the most common source of PTSD, even in the US. It is ironic that PTSD, thought not so long ago to be synonymous with an adverse effect of combat exposure in men, turns out to be a disorder that predominantly strikes civilian women. Accordingly, although combat-related PTSD continues to be the focus of considerable research effort-and deservedly so, given that war shows no signs of going away in our lifetime-researchers have increasingly focused on trying to understand the nature of PTSD in other settings.
One of these settings is exposure to terrorism. After the attacks of September 11, 2001, several epidemiologic surveys were designed to help us understand both the extent of the psychiatric adversity associated with terrorist attacks and the risk and resiliency factors that may be involved. From studies reviewed by Dr Breslau, and from additional recent surveys (for example, 2), we have come to appreciate that most individuals are remarkably resilient, even in the face of the most horrific stressors. This has led to scrutiny of the individual differences that may influence susceptibility to PTSD. Several recent studies that have emerged may shed additional light on this topic. In my work with colleagues at the University of British Columbia, we are finding a genetic basis for PTSD symptoms that explains about one-third of the variance in symptom expression (3). Of interest, this genetic vulnerability seems to include a propensity for being exposed to assaultive traumatic events (such as, serious fights, muggings, and sexual trauma). This finding raises the possibility that exposure to trauma and susceptibility to psychiatric symptoms in the aftermath of trauma may be intertwined in a way we did not altogether expect. Certainly, though, there are many forms of exposure to serious trauma (for example, exposure to terrorist attacks) that can hardly be attributed to individual behaviour. What characteristics might explain the resistance of some individuals and the vulnerability of others to adverse psychological effects associated with these exposures?
An intriguing finding in the PTSD literature is that many (but not all) studies detect reduced volume of the hippocampus in persons with PTSD. It has been speculated that this might be a direct effect of exposure to stress, resulting in hippocampal neurotoxicity (for example, 4). However, this hypothesis has been challenged on several fronts. It is clear that reduced hippocampal volume is not specific to PTSD; it has been posited as a vulnerability factor for other disorders, such as schizophrenia (5). Most recently, Gilbertson and colleagues' elegant twin study provides evidence to suggest that reduced hippocampal volume (antecedent to traumatic stress exposure) is a risk factor for vulnerability to stress-related psychological trauma, rather than an outcome (6) . Although controversial, as thoughtfully outlined in a review that accompanies the article (7), these data force us to rethink some of our popularly held notions about the etiology of PTSD. Future research efforts will surely be directed toward uncovering a common genetic basis for susceptibility to traumatic stress and hippocampal morphology. In my opinion, delineating the neurobiological basis of PTSD is one of the most exciting areas in psychiatric neuroscience. Stay tuned for future developments-they are sure to surprise.
On the clinical front, those of us who treat people with PTSD know that medical comorbidity is frequently intertwined with psychological symptoms. Patients with PTSD are among the highest users of medical services in primary care settings (8) . In their review, Asmundson and colleagues note that complaints of pain may drive much of this utilization. Ongoing chronic pain may serve as a constant reminder of the trauma that perpetuates its remembrance (that is, the "mutual maintenance" theory). Alternatively, the development of chronic pain and PTSD in the aftermath of traumatic stress may represent a shared vulnerability to both of these outcomes. Asmundson and colleagues offer us a scholarly review of these theories and present a research agenda that holds the promise of significantly illuminating our knowledge in this area. Having recently reviewed the literature on treatment of PTSD as part of a clinical case review (9), I have come to appreciate how little we know about factors that influence treatment outcomes. Chronic pain is a factor that deserves further evaluation in this regard. The article by Asmundson and colleagues raises awareness of the tremendous comorbidity of chronic pain and PTSD. It will interest clinicians and researchers alike.
I have learned a lot reading these 2 articles on PTSD. I hope that you will, too, and that you will be spurred to follow this fascinating literature as it unfolds in the years to come.
